Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2614241 | 0.98 | HPGD (0.84) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL18228404 | 0.95 | HPGD (0.96) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL254870 | 0.95 | HPGD (0.96) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL8919062 | 0.93 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL1927946 | 0.93 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL243236 | 0.93 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL27929296 | 0.93 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL436090 | 0.93 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL2678752 | 0.92 | HPGD (0.75) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9209631 | 0.91 | HPGD (0.96) | HPGDALDH1A1USP2MAPK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-12-18 | — | — | US | disclosed |
| US-12398125-B2 | Nitrogen-containing saturated heterocyclyl derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-26 | — | — | US | disclosed |
| EP-4563574-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC RING DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-06-04 | — | — | EP | disclosed |
| CN-119630649-A | Nitrogen-containing saturated heterocyclic derivative | 住友制药株式会社 | 2025-03-14 | — | — | CN | disclosed |
| US-20250051305-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12172987-B2 | Nitrogen-containing saturated heterocyclyl derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-24 | — | — | US | disclosed |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-04-18 | — | — | US | disclosed |
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2022-12-08 | — | — | US | disclosed |
| WO-2021023888-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2021-02-11 | — | — | WO | disclosed |
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-4868288-A | TITANIUM TETRACHLORIDE CATALYST | CIBA-GEIGY CORPORATION (US) | 1989-09-19 | — | — | US | disclosed |
| EP-0152377-B1 | CURABLE COMPOSITIONS AND THEIR USE | CIBA-GEIGY AG (CH) | 1987-12-09 | — | — | EP | disclosed |
| EP-0094915-B1 | CURABLE COMPOSITIONS CONTAINING METALLOCEN COMPLEXES, ACTIVATED PRIMERS OBTAINED THEREFROM AND THEIR USE | CIBA-GEIGY AG (CH) | 1987-01-21 | — | — | EP | disclosed |
| EP-0126712-B1 | CURABLE COMPOSITION AND USE THEREOF | CIBA-GEIGY AG (CH) | 1986-12-10 | — | — | EP | disclosed |
| EP-0152377-A2 | Curable compositions and their use | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | disclosed |
| US-4528382-A | Imidoyl substituted pyrroles | MCNEILAB, INC. (US) | 1985-07-09 | — | — | US | disclosed |
| EP-0126712-A1 | Curable composition and use thereof | CIBA-GEIGY AG (CH) | 1984-11-28 | — | — | EP | disclosed |
| EP-0094915-A2 | Curable compositions containing metallocen complexes, activated primers obtained therefrom and their use | CIBA-GEIGY AG (CH) | 1983-11-23 | — | — | EP | disclosed |
| US-4149941-A | ELECTROLYTIC ALKOXYLATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-17 | — | — | US | disclosed |
| US-4118500-A | Fungicidal alkoxy mono- and dialkoxy N-substituted cyclic amines | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABL1, PHKB, EEF2K | HPGD 2828/4885ALDH1A1 4455/4885USP2 1020/4885 |
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | HPGD 359/4885ALDH1A1 4022/4885USP2 1999/4885 |
| US-12172987-B2 | Nitrogen-containing saturated heterocyclyl derivative | H1-0, HTT, PRNP | HPGD 359/4885ALDH1A1 4022/4885USP2 1999/4885 |
| US-12398125-B2 | Nitrogen-containing saturated heterocyclyl derivative | H1-0, HTT, PRNP | HPGD 359/4885ALDH1A1 4022/4885USP2 1999/4885 |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | HPGD 359/4885ALDH1A1 4022/4885USP2 1999/4885 |
| US-20250051305-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | HPGD 359/4885ALDH1A1 4022/4885USP2 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.